New cancer drug cocktails set to reach the market in the next few years will test the limits of premium pricing for life-saving medicines, forcing company executives to consider fresh market strategies. The growing reluctance of governments and private insurers to fund very expensive drugs – even remarkably effective ones – points to a showdown […]

If you can find time to stand at your desk every day, a new study says it dramatically improve your health. According to study leader Dr Genevieve Healy, senior research fellow at the University of Queensland, Australia: “We found that time spent standing rather than sitting was significantly associated with lower levels of blood sugar […]

LEXINGTON, Massachusetts, August 3, 2015 /PRNewswire/ — Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), a therapy in late-stage development […]

August 3, 2015By Mark Terry, Breaking News Staff U.K.-based GlaxoSmithKline (GSK) announced today that it had re-hired Vivian Shi. Shi was formerly a GSK government affairs executive linked to an internal investigation into alleged bribery accusations at the company’s China unit. In September 2014, a southern China court fined GSK almost $500 million on […]

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis Synthon’s glatiramer acetate, a potential generic version of Copaxone®1 for the treatment of relapsing remitting multiple sclerosis is currently being reviewed by the U.S. Food and Drug Administration   NEW YORK & NIJMEGEN, Netherlands–(BUSINESS WIRE)– Pfizer Inc. and Synthon, an […]

OSAKA, Japan and FLORHAM PARK, N.J., Aug. 3, 2015 /PRNewswire/ — Shionogi today announced that once-daily naldemedine met its primary and secondary endpoints in a phase III study (COMPOSE II) for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. Naldemedine is an investigational, oral, peripherally acting mu-opioid receptor antagonist (PAMORA). […]

When we type or perform other precise tasks, our brains and muscles usually work together effortlessly. But when a neurological disease or spinal cord injury severs the connection between the brain and limbs, once-easy motions become difficult or impossible. In recent years researchers have sought to give people suffering from injury or disease some restored […]

Transaction underscores Teva’s “personalized-medicine” approach to treatment optimization across a spectrum of specialty and generics development programs and lifecycle management initiatives Teva gains exclusive rights to Immuneering’s cutting-edge analytics to advance treatments for diseases of the CNS   JERUSALEM & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and privately-held Immuneering Corporation today […]

SynbiCITE funds Prokarium to complete pre-clinical development Keele and London, UK, 3rd August 2015 / Sciad Newswire / Prokarium Ltd, a biotechnology company developing transformational oral vaccines, today announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology. The £498k project is funded at £377k from SynbiCITE and £121k from Prokarium […]

DURHAM, N.C., Aug. 3, 2015 /PRNewswire-iReach/ — A study released today in STEM CELLS Translational Medicine shows the promise of stem cells for growing new cartilage to replace the tissue damaged by osteoarthritis or injury. That’s good news for the rapidly growing number of people undergoing knee and hip replacements each year nearly a million […]